Strategic communication can mean either communicating a concept, a process, or data that satisfies a long term strategic goal of an organization by allowing facilitation of advanced planning, or communicating over long distances usually using international telecommunications or dedicated global network assets to coordinate actions and activities of operationally significant commercial, non-commercial and military business or combat and logistic subunits. It can also mean the related function within an organization, which handles internal and external communication processes. Strategic communication can also be used for political warfare. Wikipedia.


Time filter

Source Type

Computer-implemented methods for providing real-time customer, patient or accountability, security, consumer and employee metrics include: providing at least one strategic goal; providing at least one metric associated with the at least one strategic goal; providing at least one communication channel between a customer and a company; providing at least one communication code; utilizing the at least one communication code to access the at least one communication channel; providing a survey tool to the customer using the at least one communication channel; capturing data from the survey tool in a database; converting the captured data to the at least one metric; and providing the at least one metric on a dashboard application. An executable software application that implements the computer-implemented method disclosed is also contemplated.


SUMMIT COMPLETES ENROLMENT OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Oxford, UK, 15 May 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today announces that it has completed enrolment in PhaseOut DMD, a Phase 2 proof of concept clinical trial of the utrophin modulator, ezutromid, in patients with DMD. PhaseOut DMD aims to provide proof of concept for ezutromid through measures of a number of endpoints related to muscle structure, health and function. The Company believes the trial could provide valuable insight into utrophin modulation as a potential disease-modifying treatment for all patients with DMD, regardless of the underlying dystrophin mutation. With the dosing of the last patient in the trial, the Company has triggered a $22 million milestone payment as part of the Company's licence and collaboration agreement with Sarepta Therapeutics, Inc. "Completing enrolment in PhaseOut DMD is a major step in the development of ezutromid as we seek to understand if this utrophin modulator has positive effects on muscle structure leading to changes in muscle health and function in patients with DMD," said Dr David Roblin, Chief Operating Officer and President of R&D of Summit. "Utrophin modulation has potential as a universal treatment option for patients with DMD, and we look forward to the 24-week data readout expected in the first quarter of 2018." PhaseOut DMD is a 48-week open-label trial that has enrolled 40 patients at sites in the UK and the US. As part of the trial, each patient undergoes two biopsies, a baseline biopsy on enrolment and a second either at 24 or 48 weeks. In the first quarter of 2018, Summit expects to report 24-week biopsy analysis from approximately 20 patients, as well as 24-week MRI and functional data from all 40 patients enrolled in the trial. Top-line data from the complete 48-week trial are expected in the third quarter of 2018. Further information about PhaseOut DMD is available at: https://clinicaltrials.gov/ct2/show/NCT02858362 and www.utrophintrials.com. DMD is a progressive muscle wasting disease that affects around 50,000 boys and young men in the developed world. The disease is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of all muscles. There is currently no cure for DMD and life expectancy is into the late twenties. Utrophin protein is functionally and structurally similar to dystrophin. In preclinical studies, the continued expression of utrophin has a meaningful, positive effect on muscle performance. Summit believes that utrophin modulation has the potential to slow down or even stop the progression of DMD, regardless of the underlying dystrophin gene mutation. Summit also believes that utrophin modulation could potentially be complementary to other therapeutic approaches for DMD. The Company's lead utrophin modulator, ezutromid, is an orally administered, small molecule. DMD is an orphan disease, and the US Food and Drug Administration ('FDA') and the European Medicines Agency have granted orphan drug status to ezutromid. Orphan drugs receive a number of benefits including additional regulatory support and a period of market exclusivity following approval. In addition, ezutromid has been granted Fast Track designation and Rare Pediatric Disease designation by the FDA. About the Licence and Collaboration Agreement with Sarepta Therapeutics, Inc. In October 2016, Summit announced a licence and collaboration agreement with Sarepta. This granted Sarepta exclusive commercial rights to the Company's utrophin modulator pipeline, including ezutromid, in Europe, Turkey and the Commonwealth of Independent States, with an option over specific countries in Central and South America. Summit retains commercialisation rights in all other countries, including the US and Japan. Under the agreement, Summit received an upfront payment and is eligible to receive development, regulatory and sales milestones related to its utrophin modulator pipeline, including ezutromid, as well as royalties on net sales in the licensed territories. For further details, please refer to earlier RNS announcements and/or Summit's filings with the Securities and Exchange Commission. Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc). For more information, please contact: Any statements in this press release about Summit's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of Summit's product candidates, Summit's license and collaboration agreement with Sarepta and the expected receipt of any milestone payments under the agreement, the therapeutic potential of Summit's product candidates, and the timing of initiation, completion and availability of data from clinical trials, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from on-going and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for Summit's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that Summit makes with the Securities and Exchange Commission including Summit's Annual Report on Form 20-F for the fiscal year ended January 31, 2017. Accordingly readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent Summit's views only as of the date of this release and should not be relied upon as representing Summit's views as of any subsequent date. Summit specifically disclaims any obligation to update any forward-looking statements included in this press release. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).


LOS ANGELES, CA--(Marketwired - May 18, 2017) - Compass Investor Relations, a leading Investor Relations and Strategic Communications firm, today announced that Partners Mark Collinson and Elaine Ketchmere will present a webinar in conjunction with OTC Markets Group Inc. titled, "Corporate Governance Best Practices and Communication Strategies Webinar." The webinar will be held on Thursday, May 25, 2017 at 11:00am EDT. "In today's hyper-competitive capital markets, superior corporate governance and disclosure practices improve access to and lower the cost of capital. In this webinar, Directors, CEOs, CFOs and those responsible for delivering not just great performance but a well-governed company will learn what investors expect from them," said Mark Collinson, Partner at Compass Investor Relations. "The subject of corporate governance can be overwhelming for smaller issuers. We are excited to have Compass Investor Relations share their perspective on cost effective methods companies can utilize to improve their corporate governance and disclosure practices," stated Jason Paltrowitz, Executive Vice President of Corporate Services, at OTC Markets Group. Topics for the webinar will include: Whether your company is new to the public markets or is at a more mature stage with a wider shareholder base, this webinar will provide ideas to improve your corporate governance and attract new capital and wider ownership. To access the webinar, visit https://register.gotowebinar.com/register/4620203218073758211. Please log in 10 minutes before the event is scheduled to begin. About OTC Markets Group Inc. OTC Markets Group Inc. ( : OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com. OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS. About Compass Investor Relations: Compass Investor Relations was established by four veteran IR professionals. Our founding partners have a combined 40 years of investor relations experience that will give you the best possible communications strategies to develop clear, credible, consistent and compliant messages and will provide you the visibility and opportunity to communicate those messages to stakeholders efficiently and effectively. Our IR strategy is grounded in what we call the 4C's: clarity, credibility, consistency and compliance. For more information, please visit http://compassinvestorrelations.com/.


SUMMIT COMPLETES ENROLMENT OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Oxford, UK, 15 May 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today announces that it has completed enrolment in PhaseOut DMD, a Phase 2 proof of concept clinical trial of the utrophin modulator, ezutromid, in patients with DMD. PhaseOut DMD aims to provide proof of concept for ezutromid through measures of a number of endpoints related to muscle structure, health and function. The Company believes the trial could provide valuable insight into utrophin modulation as a potential disease-modifying treatment for all patients with DMD, regardless of the underlying dystrophin mutation. With the dosing of the last patient in the trial, the Company has triggered a $22 million milestone payment as part of the Company's licence and collaboration agreement with Sarepta Therapeutics, Inc. "Completing enrolment in PhaseOut DMD is a major step in the development of ezutromid as we seek to understand if this utrophin modulator has positive effects on muscle structure leading to changes in muscle health and function in patients with DMD," said Dr David Roblin, Chief Operating Officer and President of R&D of Summit. "Utrophin modulation has potential as a universal treatment option for patients with DMD, and we look forward to the 24-week data readout expected in the first quarter of 2018." PhaseOut DMD is a 48-week open-label trial that has enrolled 40 patients at sites in the UK and the US. As part of the trial, each patient undergoes two biopsies, a baseline biopsy on enrolment and a second either at 24 or 48 weeks. In the first quarter of 2018, Summit expects to report 24-week biopsy analysis from approximately 20 patients, as well as 24-week MRI and functional data from all 40 patients enrolled in the trial. Top-line data from the complete 48-week trial are expected in the third quarter of 2018. Further information about PhaseOut DMD is available at: https://clinicaltrials.gov/ct2/show/NCT02858362 and www.utrophintrials.com. DMD is a progressive muscle wasting disease that affects around 50,000 boys and young men in the developed world. The disease is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of all muscles. There is currently no cure for DMD and life expectancy is into the late twenties. Utrophin protein is functionally and structurally similar to dystrophin. In preclinical studies, the continued expression of utrophin has a meaningful, positive effect on muscle performance. Summit believes that utrophin modulation has the potential to slow down or even stop the progression of DMD, regardless of the underlying dystrophin gene mutation. Summit also believes that utrophin modulation could potentially be complementary to other therapeutic approaches for DMD. The Company's lead utrophin modulator, ezutromid, is an orally administered, small molecule. DMD is an orphan disease, and the US Food and Drug Administration ('FDA') and the European Medicines Agency have granted orphan drug status to ezutromid. Orphan drugs receive a number of benefits including additional regulatory support and a period of market exclusivity following approval. In addition, ezutromid has been granted Fast Track designation and Rare Pediatric Disease designation by the FDA. About the Licence and Collaboration Agreement with Sarepta Therapeutics, Inc. In October 2016, Summit announced a licence and collaboration agreement with Sarepta. This granted Sarepta exclusive commercial rights to the Company's utrophin modulator pipeline, including ezutromid, in Europe, Turkey and the Commonwealth of Independent States, with an option over specific countries in Central and South America. Summit retains commercialisation rights in all other countries, including the US and Japan. Under the agreement, Summit received an upfront payment and is eligible to receive development, regulatory and sales milestones related to its utrophin modulator pipeline, including ezutromid, as well as royalties on net sales in the licensed territories. For further details, please refer to earlier RNS announcements and/or Summit's filings with the Securities and Exchange Commission. Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc). For more information, please contact: Any statements in this press release about Summit's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of Summit's product candidates, Summit's license and collaboration agreement with Sarepta and the expected receipt of any milestone payments under the agreement, the therapeutic potential of Summit's product candidates, and the timing of initiation, completion and availability of data from clinical trials, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from on-going and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for Summit's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that Summit makes with the Securities and Exchange Commission including Summit's Annual Report on Form 20-F for the fiscal year ended January 31, 2017. Accordingly readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent Summit's views only as of the date of this release and should not be relied upon as representing Summit's views as of any subsequent date. Summit specifically disclaims any obligation to update any forward-looking statements included in this press release. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).


News Article | April 25, 2017
Site: globenewswire.com

Gosselies, Belgique, le 25 avril 2017, 7h CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans les domaines de l'orthopédie et des maladies osseuses, annonce aujourd'hui la publication de son Rapport annuel 2016. Bone Therapeutics est une société leader dans la thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans le domaine de l'orthopédie et des pathologies osseuses. Basée à Gosselies, Belgique, la Société dispose d'un vaste portefeuille diversifié de produits de thérapie cellulaire osseuse, en développement clinique dans divers domaines thérapeutiques ciblant des marchés caractérisés par d'importants besoins médicaux non satisfaits et des innovations limitées. Les produits de thérapie cellulaire de Bone Therapeutics sont fabriqués selon les normes des BPF les plus strictes, et protégés par un vaste portefeuille PI couvrant 9 familles de brevets. De plus amples informations sont disponibles sur notre site www.bonetherapeutics.com/fr. Certaines déclarations, croyances ou opinions du communiqué de presse sont des déclarations prospectives, et reflètent les attentes actuelles et les projections futures relatives à des événements futurs de la Société ou, le cas échéant, de ses administrateurs. De par leur nature, les déclarations prospectives impliquent un certain nombre de risques, d'incertitudes et de suppositions qui pourraient entraîner des résultats ou événements effectifs substantiellement différents de ceux exprimés de manière explicite ou implicite dans les déclarations prospectives. Ces risques, incertitudes et suppositions peuvent affecter de manière négative les résultats et effets financiers des plans et événements décrits dans le communiqué. Une multitude de facteurs, notamment, sans s'y limiter, des modifications intervenant en matière de demande, de concurrence et de technologie, peuvent avoir pour conséquence que les événements, performances ou résultats diffèrent de manière importante des développements anticipés. Les déclarations prospectives contenues dans ce communiqué de presse qui se basent sur des tendances ou des activités passées ne constituent pas des garanties que ces tendances ou activités se poursuivront à l'avenir. En conséquence, la Société rejette expressément toute obligation ou engagement de publier des mises à jour ou révisions des déclarations prospectives de ce communiqué de presse suite à une modification des prévisions ou à une modification des événements, des conditions, des suppositions ou des circonstances sur lesquelles ces déclarations prospectives sont basées. Ni la Société ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun cadre ou employé de ces personnes ne garantit que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs et aucun de ceux-ci n'accepte la moindre responsabilité en ce qui concerne l'exactitude future des déclarations prospectives contenues dans ce communiqué de presse ou la survenance effective des événements prévus. Il ne faut pas placer une confiance indue dans les déclarations prospectives, qui ne concernent que la situation telle qu'elle se présente à la date de ce communiqué de presse. Bone Therapeutics SA Thomas Lienard, Chief Executive Officer Wim Goemaere, Chief Financial Officer Tél: +32 (0)2 529 59 90 investorrelations@bonetherapeutics.com ou Pour les médias belges et internationaux: Consilium Strategic Communications Amber Fennell, Jessica Hodgson et Hendrik Thys Tél: +44 (0) 20 3709 5701 bonetherapeutics@consilium-comms.com ou Pour les médias et investisseurs français: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier et Nicolas Merigeau Tél: + 33 (0)1 44 71 94 94 bone@newcap.eu


News Article | April 17, 2017
Site: co.newswire.com

120 West Strategic Communications of Reno, Nevada announced today that Jeff Pritchard, a veteran mining and resource investor relations (IR) professional will be joining the agency to support and cultivate 120 West mining IR clients. ​Pritchard was formerly the IR consultant with Argonaut Gold (TSX: AR) and previously was a founding executive with Capital Gold Corporation (TSX: CGC) overseeing all IR and communications. “We are very excited to have Jeff join our agency,” said 120 West President and Chief Marketing Officer Ira M. Gostin. “His experience in precious metals investor relations is extremely powerful and adds great depth to our team.” ​Pritchard is a graduate of the State University of New York and has an extensive background in marketing and communications, having worked with two National Hockey League teams early in his career. He resides in Austin, Texas. 120 West is a unique provider of comprehensive communications campaigns aligned directly toward business goals. Working with both public and private companies, 120 West employs strategic engagement to drive momentum and deliver measurable communications results. Founded in 2016 by Gostin, 120 West has created an exclusive approach to investor relations, marketing and corporate communications.


PARIS, FRANCE and CHARLOTTESVILLE, VA / ACCESSWIRE / April 18, 2017 / Cellnovo Group ("Cellnovo" EN Paris: CLNV), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, and digital health company TypeZero Technologies, today announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero's Artificial Pancreas (AP) technology into Cellnovo's mobile diabetes management system. The non-exclusive worldwide agreement allows Cellnovo to commercialize a Cellnovo-TypeZero product in the future. Integration efforts are currently underway with a product launch expected in 2018. No financial terms have been disclosed. TypeZero's AP software, known as inControl AP, will be incorporated directly into Cellnovo's Bluetooth-enabled micropump. inControl AP continuously monitors blood glucose levels via a smartphone application and automatically delivers corrections to regulate blood sugar levels through an integrated insulin pump. "Our partnership with TypeZero brings us another step closer to delivering one of the first end-to-end diabetes management systems," said Sophie Baratte, Chief Executive Officer of Cellnovo. "We are confident that this strategic collaboration will result in a sophisticated product that improves the quality of life for patients with type 1 diabetes." "The future of diabetes care is rapidly progressing toward integrated solutions that simplify the device burden that people with type 1 diabetes face," said Chad Rogers, Chief Executive Officer of TypeZero. "The Cellnovo mobile diabetes management system is an ideal platform for artificial pancreas system development because of its real-time connected data and discreetness to suit the needs and lifestyle of patients. I believe the combination of our artificial pancreas technology with Cellnovo's advanced pump system can fundamentally shift the way we treat type 1 diabetes, and we're excited about that possibility." About Cellnovo An independent medical technology company specializing in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems. For further information, please visit www.cellnovo.com. About the Cellnovo Diabetes Management System Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is listed on Euronext, Compartment C ISIN: FR0012633360 - Ticker: CLNV About TypeZero Technologies, Inc. The world leader in clinically tested artificial pancreas solutions, TypeZero Technologies is a digital health and personalized medicine company dedicated to revolutionizing the treatment and management of diabetes. TypeZero is combining next-generation data science techniques, proven metabolic models, and modern engineering practices to develop customized analytics tools and blood glucose control solutions to help people with diabetes improve their health and lives. TypeZero's current solutions include a smartphone-based artificial pancreas system, therapy optimization tools for health care providers, and advisory applications for smart insulin pens. To learn more, visit www.typezero.com. Contact Cellnovo Chief Executive Officer Sophie Baratte investors@cellnovo.com NewCap Investor Relations Tristan Roquet Montégon + 33 1 44 71 00 16 Media Relations in France Nicolas Merigeau + 33 1 44 71 94 98 cellnovo@newcap.eu Consilium Strategic Communications Media Relations in United Kingdom Chris Gardner, Chris Welsh, Laura Thornton +44 20 3709 5700 cellnovo@consilium.com TypeZero Technologies, Inc. Meagan Collins Senior Operations Manager mcollins@typezero.com (434) 284-8919 SOURCE: Cellnovo Group ReleaseID: 459894


Gosselies, Belgique, le 26 avril 2017, 7h CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans les domaines de l'orthopédie et des maladies osseuses, informe ses actionnaires que son assemblée générale se tiendra le jeudi 26 mai 2017 à 16h dans les locaux de la Société, 37 Rue Auguste Piccard, 6041 Gosselies, Belgique. Les documents et renseignements préparatoires relatifs à cette assemblée sont tenus à la disposition des actionnaires et peuvent être consultés sur le site internet de la Société à l'adresse suivante : www.bonetherapeutics.com, dans la rubrique Investisseurs / Assemblée Générale, selon les dispositions légales et réglementaires applicables. Bone Therapeutics est une société leader dans la thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans le domaine de l'orthopédie et des pathologies osseuses. Basée à Gosselies, Belgique, la Société dispose d'un vaste portefeuille diversifié de produits de thérapie cellulaire osseuse, en développement clinique dans divers domaines thérapeutiques ciblant des marchés caractérisés par d'importants besoins médicaux non satisfaits et des innovations limitées. Les produits de thérapie cellulaire de Bone Therapeutics sont fabriqués selon les normes des BPF les plus strictes, et protégés par un vaste portefeuille PI couvrant 9 familles de brevets. De plus amples informations sont disponibles sur notre site www.bonetherapeutics.com/fr. Certaines déclarations, croyances ou opinions du communiqué de presse sont des déclarations prospectives, et reflètent les attentes actuelles et les projections futures relatives à des événements futurs de la Société ou, le cas échéant, de ses administrateurs. De par leur nature, les déclarations prospectives impliquent un certain nombre de risques, d'incertitudes et de suppositions qui pourraient entraîner des résultats ou événements effectifs substantiellement différents de ceux exprimés de manière explicite ou implicite dans les déclarations prospectives. Ces risques, incertitudes et suppositions peuvent affecter de manière négative les résultats et effets financiers des plans et événements décrits dans le communiqué. Une multitude de facteurs, notamment, sans s'y limiter, des modifications intervenant en matière de demande, de concurrence et de technologie, peuvent avoir pour conséquence que les événements, performances ou résultats diffèrent de manière importante des développements anticipés. Les déclarations prospectives contenues dans ce communiqué de presse qui se basent sur des tendances ou des activités passées ne constituent pas des garanties que ces tendances ou activités se poursuivront à l'avenir. En conséquence, la Société rejette expressément toute obligation ou engagement de publier des mises à jour ou révisions des déclarations prospectives de ce communiqué de presse suite à une modification des prévisions ou à une modification des événements, des conditions, des suppositions ou des circonstances sur lesquelles ces déclarations prospectives sont basées. Ni la Société ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun cadre ou employé de ces personnes ne garantit que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs et aucun de ceux-ci n'accepte la moindre responsabilité en ce qui concerne l'exactitude future des déclarations prospectives contenues dans ce communiqué de presse ou la survenance effective des événements prévus. Il ne faut pas placer une confiance indue dans les déclarations prospectives, qui ne concernent que la situation telle qu'elle se présente à la date de ce communiqué de presse. Bone Therapeutics SA Thomas Lienard, Chief Executive Officer Wim Goemaere, Chief Financial Officer Tél: +32 (0)2 529 59 90 investorrelations@bonetherapeutics.com ou Pour les médias belges et internationaux: Consilium Strategic Communications Amber Fennell, Jessica Hodgson et Hendrik Thys Tél: +44 (0) 20 3709 5701 bonetherapeutics@consilium-comms.com ou Pour les médias et investisseurs français: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier et Nicolas Merigeau Tél: + 33 (0)1 44 71 94 94 bone@newcap.eu


News Article | May 5, 2017
Site: www.prnewswire.com

"The SGDC inaugurates a new era in the history of telecommunications in Brazil, because now we can take internet via satellite to 100% of the Brazilian territory, generating social and economic benefits. We will be illuminating Brazil, with broadband internet, generating social and digital inclusion in schools, hospitals, health posts and, above all, increasing the competitiveness of Brazil," said Antonio Loss, President of Telebras. As a joint venture between Embraer and Telebras Visiona is responsible for the structuring and integration of the SGDC Program, acting among other activities in the improvement of requirements, selection and management of suppliers, validation of engineering reports, production monitoring and system tests required for mission success. For more than two years, Visiona engineers worked side by side with ThalesAlenia professionals in France in the development and production of the satellite under the technology absorption program, acquiring knowledge that will be fundamental to increase the Brazilian content of the future space programs. With an international presence and also a player in the markets for remote sensing and satellite telecommunications services, Visiona should leverage the knowledge acquired during the SGDC program to propose solutions incorporating the state-of-the-art in space construction and application technologies for the National Program Of Space Activities (PNAE) and the Strategic Program of Space Systems (PESE), always seeking the development of the Brazilian industry. ABOUT VISIONA Visiona Tecnologia Espacial S.A. is a company of the Embraer and Telebras groups, constituted with the initial objective of working on the integration of the Brazilian Government's Geostationary Defense and Strategic Communications Satellite System (SGDC), which aims to meet the Government's satellite communications needs Including the National Broadband Program (PNBL) and a broad spectrum of strategic defense communications. Visiona also aims to act as a satellite integrating company, focusing on the demands of the National Space Activities Program (PNAE / AEB) and the Strategic Space Systems Program (PESE / FAB). ABOUT TELEBRAS Telecomunicacoes Brasileiras S.A. - TELEBRAS is a publicly traded joint stock company, a strategic provider of telecommunications solutions for the Public Administration and the market, acting as agent for local development and promoting the democratization of access to information. It offers dedicated Internet access services to telecommunication service providers, which have authorization issued by Anatel; In addition to providing infrastructure to telecommunications services provided by private companies, States, Federal District, Municipalities and non-profit entities. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/visiona-announces-successful-launch-of-brazilian-geostationary-satellite-300452284.html


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: DRS-04-2014 | Award Amount: 1.38M | Year: 2015

The European Union (EU) faces a growing health security threat posed by pandemics due to the convergence of risk factors driving disease emergence, amplification and dissemination of pathogens with pandemic potential. Protecting the health and security of citizens in the EU in the face of these pandemic threats requires a coherent response by all stakeholders driven by effective pandemic risk management. PANDEM will contribute to the reduction in the health, socio-economic and security consequences of future pandemics so that society will be better prepared at regional, national, EU and global level. PANDEM will assess current pandemic preparedness and response tools, systems and practice at national, EU and global level in priority areas including risk assessment and surveillance, communication and public information, governance and legal frameworks. PANDEM will then identify gaps and improvement needs leading to the development of viable innovative concepts and analysis of the feasibility of a future demonstration project to strengthen capacity-building for pandemic risk management in the EU. PANDEM specifically addresses the needs and priorities detailed in the Horizon 2020 Work Programme crisis management topic DRS-4. PANDEM will focus on the needs and requirements of users and first responders across the spectrum of pandemic risk management. PANDEM will bring together highly skilled and multi-disciplinary senior experts from the health, security, defence, microbiology, communications, information technology and emergency management fields. Given the cross-border and multi-sectoral context of the health and security challenge for building pandemic risk management capacity, a systems-based methodology will be applied and the final outcome will be developed for use in a pan-European setting.

Loading Strategic Communications collaborators
Loading Strategic Communications collaborators